Details of Disease

General Information of Disease (ID: DISQU4Q5)

• Disease Name: Artery stenosis
• Disease Class: BD52: Arteries/arterioles disorder
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISQU4Q5: Artery stenosis
• ICD Code:
  ICD-11: ICD-11: BD52
  ICD-10: ICD-10: I51.89
• Disease Identifiers:
  MONDO ID: MONDO_0009938
  MESH ID: D011666
  UMLS CUI: C1956257
  OMIM ID: 265500
  MedGen ID: 408291
  HPO ID: HP:0001642

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Biolimus a9	DM9X4TT	Approved	Small molecular drug	[1]
Novolimus	DM6ZPLQ	Approved	NA	[2]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AGI-1067	DMYN3IH	Phase 3	Small molecular drug	[3]
Motexafin lutetium	DM8K5Z6	Phase 3	Small molecular drug	[4]
Preverex	DMZT8FS	Phase 2	Small molecular drug	[5]
PVS-10200	DMIO4W2	Phase 1/2	NA	[6]
VAN-10-4-eluting stent	DM3ZW6A	Phase 1	NA	[7]

This Disease is Treated as An Indication in 6 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BO-653	DMKF7BO	Discontinued in Phase 2	Small molecular drug	[8]
FK-633	DMQ3O4C	Discontinued in Phase 2	Small molecular drug	[9]
NOStentin	DMWDE8K	Discontinued in Phase 1	NA	[10]
NV-27	DM4D86A	Terminated	NA	[12]
RWJ-58259	DMYXD6A	Terminated	Small molecular drug	[13]
SDZ-MTH-958	DMKCXBJ	Terminated	NA	[14]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MV-6401	DMUAAH9	Preclinical	Small molecular drug	[11]

This Disease is Treated as An Indication in 5 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AIM-501	DMCJS7B	Investigative	NA	[15]
INC-106	DM8E4HB	Investigative	Antibody	[16]
Mammalian sterile 20-like kinase 1 gene eluting stent	DM8P52Z	Investigative	NA	[15]
MGN-2677	DMZFC7Q	Investigative	NA	[15]
PC-mab	DMUT7PN	Investigative	Monoclonal antibody	[15]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
PTPN11	TT7WUAV	Limited	Genetic Variation	[17]
IGFBP7	TTUQ01B	moderate	Genetic Variation	[18]
CDK13	TTRIM0E	Strong	Genetic Variation	[19]
GATA4	TT1VDN2	Strong	Genetic Variation	[20]
MAP2K1	TTIDAPM	Strong	Genetic Variation	[21]

This Disease Is Related to 5 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ELN	OTFSO7PG	Limited	Genetic Variation	[22]
GALNT1	OTO3RO36	Limited	Genetic Variation	[23]
JAG1	OT3LGT6K	Strong	Genetic Variation	[24]
LZTR1	OTIDM6XO	Strong	CausalMutation	[25]
SOS1	OTTCWXC3	Strong	Biomarker	[26]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Clinical pipeline report, company report or official report of Elixir.
• [3] ClinicalTrials.gov (NCT00066898) ARISE Aggressive Reduction of Inflammation Stops Events. U.S. National Institutes of Health.
• [4] Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 1;14(15):4869-76.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5334).
• [6] ClinicalTrials.gov (NCT01099215) Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH). U.S. National Institutes of Health.
• [7] Drug-Eluting Stent for High Risk Patients. University of Strathclyde Glasgow. 2015
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004808)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006561)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013241)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013851)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033458)
• [13] RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev. 2003 Winter;21(4):313-26.
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005235)
• [15] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 34).
• [17] The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome.Mol Genet Genomic Med. 2019 Apr;7(4):e00581. doi: 10.1002/mgg3.581. Epub 2019 Feb 19.
• [18] Mutation of IGFBP7 causes upregulation of BRAF/MEK/ERK pathway and familial retinal arterial macroaneurysms. Am J Hum Genet. 2011 Aug 12;89(2):313-9. doi: 10.1016/j.ajhg.2011.07.010.
• [19] Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders.Genome Med. 2017 Aug 14;9(1):73. doi: 10.1186/s13073-017-0463-8.
• [20] A novel mutation of GATA4 (K319E) is responsible for familial atrial septal defect and pulmonary valve stenosis.Gene. 2014 Jan 25;534(2):320-3.
• [21] Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet. 2008 Jan;73(1):62-70. doi: 10.1111/j.1399-0004.2007.00931.x. Epub 2007 Nov 27.
• [22] Spontaneous development and rupture of pulmonary artery aneurysm: a rare complication in an infant with peripheral pulmonary artery stenoses due to mutation of the elastin gene.Pediatr Cardiol. 2008 Mar;29(2):438-41. doi: 10.1007/s00246-007-9096-9. Epub 2007 Oct 3.
• [23] Galnt1 is required for normal heart valve development and cardiac function.PLoS One. 2015 Jan 23;10(1):e0115861. doi: 10.1371/journal.pone.0115861. eCollection 2015.
• [24] Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis.Hum Mutat. 2010 May;31(5):594-601. doi: 10.1002/humu.21231.
• [25] Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants.Genet Med. 2018 Oct;20(10):1175-1185. doi: 10.1038/gim.2017.249. Epub 2018 Feb 22.
• [26] Rare copy number variants in a population-based investigation of hypoplastic right heart syndrome.Birth Defects Res. 2017 Jan 20;109(1):8-15. doi: 10.1002/bdra.23586.